PARIS & FORT WORTH, Texas–(BUSINESS WIRE)– #Finance–Eyevensys developing non-viral gene therapies for retinal and other ophthalmic diseases, announces that it has completed a $30M Series B financing.
Author: Business Wire
Midwest Vision Partners Announces Partnership With Michigan Eye Institute
CHICAGO & FLINT, Mich.–(BUSINESS WIRE)–Midwest Vision Partners (“MVP”) is pleased to announce its partnership with Michigan Eye Institute (“MEI”). This represents MVP’s first partnership in Michigan. MVP is a people-focused eye care management servic…
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the appoint…
Stanton Optical, Leading Eye Care Provider, Opens Sacramento Area Location
SACRAMENTO, Calif.–(BUSINESS WIRE)– #California–Stanton Optical, a retail brand of Now Optics – a leading eye care provider – opened a new store in Florin, California, at 420 Florin Rd.
Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of an article concerning the company’s inve…
Global Ophthalmology Devices Market 2019-2023| Evolving Opportunities with Alcon Inc. and Bausch Health Companies Inc. | Technavio
LONDON–(BUSINESS WIRE)– #HealthcareDevices–Global ophthalmology devices market is poised to grow by USD 13.9 billion during 2019-2023, progressing at a CAGR of close to 4%.
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
MARIETTA, Ohio–(BUSINESS WIRE)– #AAGP–ProtoKinetix AAGP® Dry Eye Therapy Testing Results
Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Monday, Janu…
PhotoniCare Announces FDA Clearance for First-In-Class Technology for Imaging the Ear
CHAMPAIGN, Ill.–(BUSINESS WIRE)–PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing physicians with better diagnostic tools, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance…
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Uveitis Market Pipeline Review & Analysis, H2 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Uveitis – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Report Highlights The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Uveitis – Pipeline Review, H2 20…
OTITOPIC™ Announces Results of Dose-Finding PK/PD Study for ASPRIHALE® Dry Powder Inhalation of Aspirin for Acute Myocardial Infarction (MI)
LOS ANGELES–(BUSINESS WIRE)–OTITOPIC™ Announces Results of Dose-Finding PK/PD Study for ASPRIHALE® Dry Powder Inhalation of Aspirin for Acute Myocardial Infarction (MI)
North America Dry Eye Syndrome Market by Disease Type, Drug Type, Product, Distribution Channel and Region – Forecast to 2024 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Dry Eye Syndrome Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering. The North America dry eye syndrome market reached…
Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
EnChroma Introduces Line of Lenses for Low Vision and Age-Related Eye Conditions
BERKELEY, Calif. & MUNICH–(BUSINESS WIRE)– #colorishere–New EnChroma Lenses for Low Vision/Age-Related Eye Conditions Offer Four Options for Consistent Tint Density, Superior Glare Reduction; Enhanced Color
Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced additional patient dat…
Global Optical Lens Edger Market Drivers, Restraints & Opportunities During the Forecast Period, 2018-2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–elThe “Optical Lens Edger Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026” report has been added to ResearchAndMarkets.com’s offering. Global Optical Lens Edger Market: Overview This repor…
Acucela to Participate in Biotech Showcase™ 2020
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596), announced today its participation in Biotech Showcase™ 2020, being held in…
Acucela Announces Publication of Pre-clinical Data for Emixustat Hydrochloride
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of pre-clinical data related to the company…
2019年、5736人の世界で最も貧しい人々がテジ・コーリ角膜インスティテュートで視力を回復
ロンドン–(BUSINESS WIRE)–（ビジネスワイヤ） — ハイデラバードのテジ・コーリ角膜インスティテュートが創立4周年を迎え、テジ・コーリ財団は2020年より新たに1400万ドルの資金を提供します。2019年、5736人がテジ・コーリ角膜インスティテュートで失明や重度の視覚障害を治療しました。これは、ロンドンのテジ・コーリ財団と、世界保健機関協力センターであるハイデラバードのLVプラサド眼科研究所との共同活動です。 テジ・コーリ角膜インスティテュートは、2015年12月に設立され、治…